Press Release

CRISPR Therapeutics to Participate in Four Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 21, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced that members of its senior management team are scheduled to present at four upcoming Investor Conferences.

2018 RBC Capital Markets Global Healthcare Conference
Date: Thursday, February 22, 2018
Presentation: 8:00-8:25 AM ET
Webcast available under Investor Relations tab at

Barclays Global Healthcare Conference
Date: Tuesday, March 13, 2018
Presentation: 3:20-3:45 PM ET

Guggenheim Conference on Disruptive Technologies in Immuno-Oncology
Date: March 27th, 2018

17th Annual Needham Healthcare Conference
Date: March 28th, 2018
Presentation: 3:30 PM ET

About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit

Jennifer Paganelli
WCG on behalf of CRISPR
+1 347-658-8290

Chris Erdman
+1 617.307.7227
Chris Brinzey
Westwicke Partners for CRISPR
+1 339-970-2843

Primary Logo

CRISPR Therapeutics AG

You are now leaving the CRISPR Therapeutics website.

CRISPR Therapeutics is not responsible for the content or availability of third-party sites.